nach oben

Erschienen in:

25.09.2022 | Original Article

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study

verfasst von: Amandeep Singh, Arka De, Mini P. Singh, Sahaj Rathi, Nipun Verma, Madhumita Premkumar, Sunil Taneja, Ajay Duseja, Virendra Singh

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Patients with cirrhosis have a higher risk of severe COVID-19 and mortality and are high-priority patients for vaccination. However, cirrhotics were excluded from the phase 2/3 vaccine trials. Hence, we aimed to assess the antibody response and safety of Covishield (ChAdOx1nCoV-19) among patients with cirrhosis.

Methods

Patients who attended the tele-hepatology services at our institute from March 2020 to June 2021 and diagnosed with cirrhosis as per their medical records were telephonically interviewed in July 2021 using a pre-specified questionnaire. Patients who had completed 2 doses of ChAdOx1-nCOV (with the 2^nd dose administered at least 2 weeks back) and without history of documented COVID-19 infection (pre- or post-vaccination) were tested for antibodies against the spike protein. Seropositive patients were divided into high, moderate, and low antibody responses based on the signal/cut-off.

Results

We interviewed 784 patients with cirrhosis. At least 1 dose of ChAdOx1-nCOV was received by 231 patients among whom 134 (58%) had received 2 doses. Documented COVID-19 was reported in 3.9% patients who received at least 1 dose of ChAdOx1-nCOV including breakthrough infections in 3.7% patients vaccinated with 2 doses. Local and systemic adverse events were reported by 42% and 22.1% patients. None developed anaphylaxis, acute decompensation, acute-on-chronic liver failure, or other serious adverse events requiring hospitalization. Seroconversion was documented in 81 (92%) out of 88 patients. No difference was observed in level of antibody response between patients with compensated and decompensated cirrhosis (p = 0.12).

Conclusion

Our preliminary data suggest that ChAdOx1-nCOV is safe with high seroconversion rates in patients with cirrhosis.

Nur mit Berechtigung zugänglich

Sharma A, Patnaik I, Kumar A, Gupta R. COVID-19 vaccines in patients with chronic liver disease. J Clin Exp Hepatol. 2021;11:720–726.CrossRef

Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.CrossRef

Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. Hepatology. 2020;71:2135–2148.CrossRef

Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18:348–364.CrossRef

Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–577.CrossRef

Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–1071.CrossRef

Mehtani R, De A, Mishra S, Roy A, Gandotra A, Verma N et al. Natural history of non-severe COVID-19 in patients with liver disease. Hepatology. 2021;74:332A.

Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK et al. American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology. 2021;74:1049–1064.CrossRef

Alqahtani SA, Barry M, Memish Z, Hashim A, Alfares MA, Alghamdi SA et al. Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation. Saudi J Gastroenterol. 2021;27:201–207.CrossRef

10.

Aggeletopoulou I, Davoulou P, Konstantakis C, Thomopoulos K, Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017. https://doi.org/10.1002/rmv.1942.CrossRef

11.

McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181:757–760. https://doi.org/10.1086/315245.CrossRef

12.

Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of igg antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58:e01243-e1320.CrossRef

13.

Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol. 2020;58:e02005-e2020. https://doi.org/10.1128/JCM.02005-20.CrossRef

14.

Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015–1027. https://doi.org/10.1056/NEJMoa2031893.CrossRef

15.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478.CrossRef

16.

Asano M, Okada H, Itoh Y, Hirata H, Ishikawa K, Yoshida E et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. Int J Infect Dis. 2022;114:165–174. https://doi.org/10.1016/j.ijid.2021.10.030.CrossRef

17.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993.CrossRef

18.

Hoque A, Barshan AD, Chowdhury FUH, Fardous J, Hasan MJ, Khan MAS et al. Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: a prospective observational study. Infect Drug Resist. 2021;19:5491–5500.CrossRef

19.

Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A et al. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021;39:6492–6509.CrossRef

20.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.CrossRef

21.

Humphreys IR, Godkin AJ. The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic. QJM. 2021;114:163–165.CrossRef

22.

Hung IFN, Poland GA. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854–855.CrossRef

23.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–891.CrossRef

24.

Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75:1434–1439.CrossRef

25.

John BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao HH, Dahman B. Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology. 2022. https://doi.org/10.1002/hep.32337.CrossRef

26.

Willuweit K, Frey A, Passenberg M, Korth J, Saka N, Anastasiou OE et al. Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers. Vaccines (Basel) 2022;10:377. https://doi.org/10.3390/vaccines10030377.CrossRef

27.

Ruether DF, Schaub GM, Duengelhoef PM, Haag F, Brehm TT, Fathi A et al. SARS-CoV2-specific humoral and t-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol. 2022;20:162-172.e9. https://doi.org/10.1016/j.cgh.2021.09.003.CrossRef

28.

Bakasis AD, Bitzogli K, Mouziouras D, Pouliakis A, Roumpoutsou M, Goules AV et al. Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases. Viruses 2022;14:207. https://doi.org/10.3390/v14020207.CrossRef

29.

Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. Clin Gastroenterol Hepatol. 2021:S1542–3565(21)01346-X. https://doi.org/10.1016/j.cgh.2021.12.022.

30.

Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, et al. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. 2022. doi: https://doi.org/10.1007/s12072-022-10332-9.

31.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595–1606.CrossRef

32.

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26:1478–1488.CrossRef

33.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211.CrossRef

34.

Khoury DS, Cromer D, Reynaldi A, Sclub TE, Wheatley AK, Juno JA, et al. What level of neutralising antibody protects from COVID-19? medRxiv preprint doi: https://doi.org/10.1101/2021.03.09.21252641.

35.

Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114–119. https://doi.org/10.1038/s41586-021-03944-y.

36.

Ghosh S, Shankar S, Chatterjee K, Chatterjee K, Yadav AK, Pandya K et al. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: interim results of VIN-WIN cohort study. Med J Armed Forces India. 2021;77:S264–S270.CrossRef

37.

Rana K, Mohindra R, Pinnaka L. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;385:e7.CrossRef

38.

John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D et al. Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021;181:1306–1314.CrossRef

39.

Marjot T, Webb GJ, Barritt AS, Ginès P, Lohse AW, Moon AM et al. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021;6:156–158.CrossRef

Titel: Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
verfasst von: Amandeep Singh
Arka De
Mini P. Singh
Sahaj Rathi
Nipun Verma
Madhumita Premkumar
Sunil Taneja
Ajay Duseja
Virendra Singh
Publikationsdatum: 25.09.2022
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-022-07641-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study

Abstract

Introduction

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Achalasia Quality Indicator Adherence

Narrowing the Quality Chasm in Achalasia

Upadacitinib Is Safe and Effective for Crohn’s Disease: Real-World Data from a Tertiary Center

Rising Rates of Severe Obesity in Adults Younger Than 50 Correspond to Rise in Hospitalizations for Non-malignant Gastrointestinal Disease

Histologic Severity of Nonalcoholic Fatty Liver Disease Associates with Reduced Bone Mineral Density in Children

Accuracy and Inter-observer Agreement Among Endoscopists for Visual Identification of Colorectal Polyps Using Endoscopy Images

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin